http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 NEWTON, Mass., November 12, 2009 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that... http://pharmalicensing.com/redirs/news_rss//public/news/view/499902/4/0/novelos-therapeutics-closes-last-tranche-in-9-million-private-placement http://pharmalicensing.com/redirs/news_rss//public/news/view/499902/4/0/novelos-therapeutics-closes-last-tranche-in-9-million-private-placement Woburn, MA, November 10, 2009 -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a... http://pharmalicensing.com/redirs/news_rss//public/news/view/499620/4/0/biovex-completes-70-million-financing-to-conclude-pivotal-study-with-its-pioneering-cancer-treatment-oncovexgm-csf http://pharmalicensing.com/redirs/news_rss//public/news/view/499620/4/0/biovex-completes-70-million-financing-to-conclude-pivotal-study-with-its-pioneering-cancer-treatment-oncovexgm-csf WALTHAM, Mass.--Nov. 4, 2009-- Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, announced today that its board of... http://pharmalicensing.com/redirs/news_rss//public/news/view/498882/4/0/phase-forward-announces-share-repurchase-program http://pharmalicensing.com/redirs/news_rss//public/news/view/498882/4/0/phase-forward-announces-share-repurchase-program PLAINVIEW, N.Y.--Nov. 3, 2009-- Veeco Instruments Inc. (Nasdaq: VECO) announced today that it has closed its recent public offering of common stock. Veeco sold 5,750,000 shares of common stock... http://pharmalicensing.com/redirs/news_rss//public/news/view/498534/4/0/veeco-completes-common-stock-offering http://pharmalicensing.com/redirs/news_rss//public/news/view/498534/4/0/veeco-completes-common-stock-offering CALGARY, AB - November 3, 2009 - Oncolytics Biotech Inc. ("Oncolytics" or the "Corporation") (TSX:ONC; NASDAQ:ONCY) announces, that pursuant to the accelerated expiry of those warrants issued on May... http://pharmalicensing.com/redirs/news_rss//public/news/view/498559/4/0/oncolytics-biotech http://pharmalicensing.com/redirs/news_rss//public/news/view/498559/4/0/oncolytics-biotech Montreal, Canada, November 2, 2009 - ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare... http://pharmalicensing.com/redirs/news_rss//public/news/view/498616/4/0/art-secures-up-to-1-2-million-in-interim-financing-in-connection-with-the-pursuit-of-its-strategic-review-process-and-files-a-notice-of-intention-under-the-bankruptcy-and-insolvency-act http://pharmalicensing.com/redirs/news_rss//public/news/view/498616/4/0/art-secures-up-to-1-2-million-in-interim-financing-in-connection-with-the-pursuit-of-its-strategic-review-process-and-files-a-notice-of-intention-under-the-bankruptcy-and-insolvency-act INCLINE VILLAGE, Nev., Nov. 2, 2009 -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it closed on its previously disclosed $300 million securitization transaction intended to monetize... http://pharmalicensing.com/redirs/news_rss//public/news/view/498511/4/0/pdl-biopharma-announces-closing-of-300-000-000-securitization-transaction http://pharmalicensing.com/redirs/news_rss//public/news/view/498511/4/0/pdl-biopharma-announces-closing-of-300-000-000-securitization-transaction PORTO, Portugal, Oct. 30, 2009-- Cancer patients in northern Portugal will gain access to advanced cancer treatments with the acquisition of seven new treatments machines from Varian Medical Systems... http://pharmalicensing.com/redirs/news_rss//public/news/view/498228/4/0/varian-medical-systems-selected-to-supply-major-project-to-bring-advanced-radiotherapy-treatments-to-north-of-portugal-cancer-patients-to-benefit-from-state-of-the-art-rapidarc-and-novalis-tx-installations http://pharmalicensing.com/redirs/news_rss//public/news/view/498228/4/0/varian-medical-systems-selected-to-supply-major-project-to-bring-advanced-radiotherapy-treatments-to-north-of-portugal-cancer-patients-to-benefit-from-state-of-the-art-rapidarc-and-novalis-tx-installations VIENNA, Va., Oct. 26 -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that it has received over $10 million over the past 60 days through the exercise of warrants by investors to purchase the... http://pharmalicensing.com/redirs/news_rss//public/news/view/497925/4/0/cel-sci-corporation-strengthens-balance-sheet-through-receipt-of-10-million-from-warrant-exercises http://pharmalicensing.com/redirs/news_rss//public/news/view/497925/4/0/cel-sci-corporation-strengthens-balance-sheet-through-receipt-of-10-million-from-warrant-exercises ST. PAUL, Minn.----Oct. 23, 2009-- St. Jude Medical, Inc. (NYSE:STJ) announced today that its Board of Directors has authorized a share repurchase of up to $500 million of its outstanding common... http://pharmalicensing.com/redirs/news_rss//public/news/view/497042/4/0/st-jude-medical-board-of-directors-authorizes-share-repurchase http://pharmalicensing.com/redirs/news_rss//public/news/view/497042/4/0/st-jude-medical-board-of-directors-authorizes-share-repurchase